Infrasonix Inc. Exclusively Licenses Groundbreaking Detection Technology

Infrasonix Inc. Exclusively Licenses Groundbreaking Detection Technology 2017-02-18T22:34:18+00:00

Infrasonix Inc. Exclusively Licenses Groundbreaking Detection Technology for Human Cardiovascular Disease

Infrasonix is developing a diagnostic device for front line medical practitioners that is intended to detect and quantify cardiovascular disease.

ATLANTA, Feb. 20, 2017 – Infrasonix Inc., an Atlanta technology company, today announced a license agreement with the National Aeronautics and Space Administration (NASA) giving it the exclusive right to use NASA-developed infrasound technology in detection devices used to monitor human health. Infrasonix will use the technology to develop and market new-to-the-healthcare-industry devices, including one intended to dramatically improve a physician’s ability to detect and diagnose cardiovascular disease.

“This technology could revolutionize global cardiovascular care,” said Nigel Flynn, chairman and president of Infrasonix Inc. “Our goal is to apply this technology cost effectively during an annual physical exam and help primary care physicians detect the extent of constricted blood flow in the human cardiovascular system. The device will quantify cardiovascular disease from the earliest years of life by gathering data that no existing stethoscope or in-office device can currently provide.

“The NASA agreement green-lights the development and testing process necessary to allow us to begin saving lives,” Flynn said.

Each year more than 800,000 people in the United States die from heart disease, stroke and other cardiovascular diseases, making it our nation’s leading cause of death and the root of 1 in 4 mortalities. Worldwide cardiovascular disease accounted for 17.3 million deaths in 2008 and is predicted to swell to 23.3 million by 2030.

Groundbreaking technology ‘hears’ sounds never before heard

For 200 years physicians have relied on the stethoscope to acquire the acoustic data necessary to detect, diagnose, and monitor cardiovascular disease. The stethoscope has aided the human ear, which can detect sound from 20 to 20,000 hertz frequency range. However, sound transmitted from a source in this range is absorbed by adjacent cellular tissue, making it difficult to accurately detect and/or identify the original source.

The groundbreaking sensor technology licensed from NASA makes it possible to detect sounds never before heard. This technology can ‘hear’ or detect and record frequencies in the 0.01- to 20-hertz range, well below current technology. This low-frequency sound is called infrasound.

The human body produces infrasound, and one key source is blood as it passes through the cardiovascular system. Because infrasound is not absorbed by adjacent cellular tissue, it emerges from the body without signal degradation, enabling physicians to ‘hear’ blood flow infrasound, which is then recorded for the quantitative measure of changes in cardiovascular health.

“Our ultimate goal is to place this device in the hands of every physician to allow them to immediately achieve two goals,” Flynn said. “First, diagnose patients with advanced disease states and ensure they receive the immediate follow-up cardiovascular care they urgently require. Secondly, work with all patients to optimize their cardiovascular health through proactive physician follow-up. In this way, I believe our technology will dramatically impact mortality rates of the world’s leading cause of death and extend human lifespan.

“Taken as a whole, we expect this technology will yield important information on conditions of the heart, cardiovascular system and other disease states that are currently difficult or impossible to detect using stethoscopes and readily available physician’s office medical technology.”

Infrasonix taps Invest Georgia Exemption intrastate crowdfunding program

Infrasonix Inc. is moving rapidly to develop world-changing healthcare technology within the State of Georgia. One program that helped Infrasonix kick-start the project is the Invest Georgia Exemption.

“The purpose of the Invest Georgia Exemption is to provide Georgia-based entrepreneurs with expanded access to capital from Georgia investors in order to develop new business ventures, expand existing operations, and create jobs in our state,” said Secretary of State Brian Kemp. “It is an attractive option for businesses looking for alternatives to traditional bank financing to fund both small-scale growth and assist businesses attempting multi-million dollar capital raises.”

Georgia became the second state in the U.S. to allow intrastate crowdfunding when Secretary Kemp enacted the Invest Georgia Exemption. Since its inception in 2011, businesses have applied for the exemption, including medical technology firms like Infrasonix, real estate financing firms, and manufacturers. Late in 2015 Secretary Kemp increased the Invest Georgia Exemption limit to allow Georgia companies to raise up to $5 million per offering from Georgia residents.